USANA Health Sciences (NYSE:USNA – Get Free Report) posted its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.22), FiscalAI reports. USANA Health Sciences had a negative net margin of 2.34% and a positive return on equity of 3.56%. The business had revenue of $205.89 million during the quarter, compared to analyst estimates of $217.42 million.
USANA Health Sciences Stock Performance
USNA traded down $0.25 during trading on Thursday, reaching $12.60. The company’s stock had a trading volume of 83,990 shares, compared to its average volume of 151,144. USANA Health Sciences has a 52-week low of $12.57 and a 52-week high of $23.59. The company’s fifty day moving average price is $14.55 and its 200-day moving average price is $17.81. The company has a market capitalization of $232.88 million, a price-to-earnings ratio of -11.02, a price-to-earnings-growth ratio of 1.98 and a beta of 0.66.
Wall Street Analyst Weigh In
Several research firms have recently commented on USNA. Wall Street Zen cut USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a research report on Monday, September 21st. Finally, Zacks Research cut shares of USANA Health Sciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, November 4th. Two investment analysts have rated the stock with a Sell rating. According to data from MarketBeat, the stock currently has an average rating of “Sell”.
About USANA Health Sciences
USANA Health Sciences, Inc. develops and sells nutritional supplements, personal care products and foods. Its offerings include vitamins and other nutrition products, skincare products under the Celavive brand, and nutrition bars. Founded in 1992 by Myron Wentz, the company uses a direct-selling model, with independent Associates and other sales channels connecting its products with customers. USANA serves markets across North America, Asia-Pacific and other international regions.
Featured Articles
- Five stocks we like better than USANA Health Sciences
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
- Midterm Fallout, NVIDIA Turmoil, Anthropic’s IPO: Is Broadcom a Steal?
- 3 Pharmaceutical Stocks That Offer Safety and Growth
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
